JP2000501698A - 尿膀胱疾患治療におけるｐｄｅ阻害剤の使用 - Google Patents

尿膀胱疾患治療におけるｐｄｅ阻害剤の使用

Info

Publication number
JP2000501698A
JP2000501698A JP9508103A JP50810397A JP2000501698A JP 2000501698 A JP2000501698 A JP 2000501698A JP 9508103 A JP9508103 A JP 9508103A JP 50810397 A JP50810397 A JP 50810397A JP 2000501698 A JP2000501698 A JP 2000501698A
Authority
JP
Japan
Prior art keywords
acid
pdei
treatment
inhibitor
urinary bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9508103A
Other languages
English (en)
Japanese (ja)
Inventor
ミカエル カールステン トラス
ステファン エッケルト
クリスチアン ゲオルグ スチエフ
ヴォルフーゲオルグ フォスマン
ウド ジョナス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2000501698A publication Critical patent/JP2000501698A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP9508103A 1995-08-08 1996-08-01 尿膀胱疾患治療におけるｐｄｅ阻害剤の使用 Pending JP2000501698A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19529102A DE19529102A1 (de) 1995-08-08 1995-08-08 Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
DE19529102.6 1995-08-08
PCT/EP1996/003393 WO1997005876A1 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Publications (1)

Publication Number Publication Date
JP2000501698A true JP2000501698A (ja) 2000-02-15

Family

ID=7768971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9508103A Pending JP2000501698A (ja) 1995-08-08 1996-08-01 尿膀胱疾患治療におけるｐｄｅ阻害剤の使用

Country Status (9)

Country Link
EP (1) EP0843553A1 (de)
JP (1) JP2000501698A (de)
AU (1) AU6702596A (de)
CA (1) CA2228314A1 (de)
DE (1) DE19529102A1 (de)
EA (1) EA199800192A1 (de)
HU (1) HUP0104619A3 (de)
WO (1) WO1997005876A1 (de)
ZA (1) ZA966698B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549480B2 (ja) * 1991-12-10 1996-10-30 ヘキストジャパン株式会社 排尿障害改善剤
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one

Also Published As

Publication number Publication date
HUP0104619A2 (hu) 2002-04-29
HUP0104619A3 (en) 2002-06-28
EP0843553A1 (de) 1998-05-27
WO1997005876A1 (en) 1997-02-20
AU6702596A (en) 1997-03-05
EA199800192A1 (ru) 1999-06-24
CA2228314A1 (en) 1997-02-20
DE19529102A1 (de) 1997-02-13
ZA966698B (en) 1998-02-09

Similar Documents

Publication Publication Date Title
US6720340B1 (en) Nicotine receptor agonists in stem cell and progenitor cell recruitment
US6287601B1 (en) Topical nitric oxide donor compositions
US9555034B2 (en) Compositions and methods for treating skin cancer associated diseases
US7820640B2 (en) Methods for treating hearing loss
US20190022225A1 (en) Protocol for increasing life expectancy in a test subject
JP3559282B2 (ja) ホスホジェステラーゼ ▲ｉｖ▼のインヒビターの新規使用
JP2002542147A (ja) 肛門直腸障害の処置のための組成物および方法
JP2001522801A (ja) 皮膚浸透増強成分
EP1477166A1 (de) Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
JP2003511110A (ja) 身体脈管における再狭窄を予防するシステムおよび装置
JP2010514790A (ja) 治療処置のための方法および組成物
US5922701A (en) Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue
EP1631294B1 (de) Verfahren zur behandlung von angstzuständen
US5891904A (en) Use of inhibitors of phosphodiesterase IV
CZ240297A3 (cs) Transdermální přípravek
WO2010019450A2 (en) Synergizing active compounds for treating inflammation and other conditions
WO2008129000A1 (en) Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders
JP2006525317A (ja) 認知および記憶を改善するための組成物
US20140377351A1 (en) Method and composition for enhancing cognition in alzheimer's patients
JP2001500113A (ja) 精神遅滞を処置する方法
AU3621097A (en) Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US8106061B2 (en) Use of phosphodiesterase inhibitors in the treatment of prostatic diseases
WO1997005876A1 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
WO1997005876A9 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
JP2002503209A (ja) 著しく改善された抗腫瘍活性によるリポソーム抗腫瘍療法